UNSPSC 51281912: Puromycin aminonucleoside

This classification denotes a protein synthesis inhibitor and miscellaneous antineoplastic antibiotic with the molecular formula C12H18N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Q580U88V8, chemically known as 6-(dimethylamino)-9-(3-amino-3-deoxy-.beta.-d-ribofuranosyl)purine, but more generally known as puromycin aminonucleoside, which bears US NIH Compound Identifier 1599.

European Medicines Agency schedules puromycin aminonucleoside or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10161MIG. Most nations, for tariff purposes, schedule puromycin aminonucleoside under HS 29419000. SMILES: CN(C)C1C2C(NCN1)N(CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O.

UNSPSC 51281912 Puromycin aminonucleoside is a Commodity code that covers procurement of this specialized nucleoside analog used in pharmaceutical research and development. State and local governments do not appear in the recent sourcing activity for this chemical reagent; the code shows no state or local contract opportunities in the available records.

The absence of state and local solicitation activity under this Commodity suggests it is procured primarily through federal research institutions, private pharmaceutical manufacturers, or academic medical centers rather than through state procurement channels. Firms evaluating this code should assess whether their customer base includes state university chemistry or pharmaceutical departments, state health department laboratories, or state-funded research initiatives that source reagents through open competitive solicitation.